• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚太地区铜绿假单胞菌感染的危险因素及初始不适当抗菌治疗的后果:系统文献回顾和荟萃分析。

Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis.

机构信息

Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033-1310, USA.

Covance Market Access Services Inc., 3rd Floor, 97 Waterloo Rd, Macquarie Park, NSW 2113, Australia.

出版信息

J Glob Antimicrob Resist. 2018 Sep;14:33-44. doi: 10.1016/j.jgar.2018.02.005. Epub 2018 Feb 15.

DOI:10.1016/j.jgar.2018.02.005
PMID:29454906
Abstract

OBJECTIVES

Treating infections of Gram-negative pathogens, in particular Pseudomonas aeruginosa, is a challenge for clinicians in the Asia-Pacific region owing to inherent and acquired antimicrobial resistance. This systematic review and meta-analysis provides updated information on risk factors for P. aeruginosa infection in Asia-Pacific as well as the consequences (e.g. mortality, costs) of initial inappropriate antimicrobial therapy (IIAT).

METHODS

Embase and MEDLINE databases were searched for Asia-Pacific studies reporting the consequences of IIAT versus initial appropriate antimicrobial therapy (IAAT) in Gram-negative bacterial infections as well as risk factors for serious P. aeruginosa infection. A meta-analysis of unadjusted mortality was performed using a random-effects model.

RESULTS

A total of 22 studies reporting mortality and 13 reporting risk factors were identified. The meta-analysis demonstrated that mortality was significantly lower in patients receiving IAAT versus IIAT, with a 67% reduction observed for 28- or 30-day all-cause mortality (odds ratio=0.33, 95% confidence interval 0.20-0.55; P<0.001). Risk factors for serious P. aeruginosa infection include previous exposure to antimicrobials, mechanical ventilation and previous hospitalisation.

CONCLUSION

High rates of antimicrobial resistance in Asia-Pacific as well as the increased mortality associated with IIAT and the presence of risk factors for serious infection highlight the importance of access to newer and appropriate antimicrobials.

摘要

目的

亚太地区临床医生在治疗革兰氏阴性病原体感染,尤其是铜绿假单胞菌感染时面临挑战,这是由于固有和获得性的抗菌药物耐药性所致。本系统评价和荟萃分析提供了亚太地区铜绿假单胞菌感染的危险因素以及初始不适当抗菌治疗(IIAT)的后果(如死亡率、成本)的最新信息。

方法

检索 Embase 和 MEDLINE 数据库,以获取报告 IIAT 与初始适当抗菌治疗(IAAT)在革兰氏阴性菌感染中的后果以及严重铜绿假单胞菌感染危险因素的亚太地区研究。使用随机效应模型对未调整的死亡率进行荟萃分析。

结果

共确定了 22 项报告死亡率的研究和 13 项报告危险因素的研究。荟萃分析表明,接受 IAAT 的患者死亡率明显低于接受 IIAT 的患者,28 天或 30 天全因死亡率降低 67%(优势比=0.33,95%置信区间 0.20-0.55;P<0.001)。严重铜绿假单胞菌感染的危险因素包括先前接触抗菌药物、机械通气和先前住院治疗。

结论

亚太地区抗菌药物耐药率高,以及 IIAT 相关的死亡率增加和严重感染的危险因素存在,突显了获得新型和适当抗菌药物的重要性。

相似文献

1
Risk factors for Pseudomonas aeruginosa infections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis.亚太地区铜绿假单胞菌感染的危险因素及初始不适当抗菌治疗的后果:系统文献回顾和荟萃分析。
J Glob Antimicrob Resist. 2018 Sep;14:33-44. doi: 10.1016/j.jgar.2018.02.005. Epub 2018 Feb 15.
2
Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis.拉丁美洲住院成人的铜绿假单胞菌感染:系统评价和荟萃分析。
BMC Infect Dis. 2020 Mar 27;20(1):250. doi: 10.1186/s12879-020-04973-0.
3
Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. 铜绿假单胞菌引起的社区获得性血流感染的发生率、预测因素和死亡率:系统评价和荟萃分析。
Clin Microbiol Infect. 2019 Aug;25(8):964-970. doi: 10.1016/j.cmi.2019.04.005. Epub 2019 Apr 14.
4
Risk factors for hospitalized patients with resistant or multidrug-resistant infections: a systematic review and meta-analysis.住院患者耐多药或多重耐药感染的危险因素:系统评价和荟萃分析。
Antimicrob Resist Infect Control. 2018 Jul 4;7:79. doi: 10.1186/s13756-018-0370-9. eCollection 2018.
5
Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).头孢洛扎/他唑巴坦对亚太地区(不包括中国、澳大利亚和新西兰)引起的医疗保健相关感染的耐药肠杆菌科和铜绿假单胞菌的活性:来自抗菌监测计划(2013-2015 年)的报告。
Int J Antimicrob Agents. 2018 Feb;51(2):181-189. doi: 10.1016/j.ijantimicag.2017.09.016. Epub 2017 Oct 6.
6
Mortality in patients with multidrug-resistant Pseudomonas aeruginosa infections: a meta-analysis.多重耐药铜绿假单胞菌感染患者的死亡率:一项荟萃分析。
Rev Soc Bras Med Trop. 2018 Jul-Aug;51(4):415-420. doi: 10.1590/0037-8682-0506-2017.
7
Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification.铜绿假单胞菌医院获得性肺炎:肺炎分类的影响
Infect Control Hosp Epidemiol. 2015 Oct;36(10):1190-7. doi: 10.1017/ice.2015.167. Epub 2015 Jul 20.
8
Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.铜绿假单胞菌菌血症患者死亡的危险因素:抗菌药物耐药性对预后的临床影响。
Microb Drug Resist. 2011 Jun;17(2):305-12. doi: 10.1089/mdr.2010.0170. Epub 2011 Mar 7.
9
Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013.亚太地区尿路感染病原体的流行病学和抗菌药物敏感性分析:2010-2013 年监测抗菌药物耐药性趋势研究(SMART)结果。
Int J Antimicrob Agents. 2016 Apr;47(4):328-34. doi: 10.1016/j.ijantimicag.2016.01.008. Epub 2016 Feb 17.
10
Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.比较碳青霉烯类药物对主要革兰氏阴性病原菌的体外活性:来自 COMPACT II 研究的亚太地区监测结果。
Int J Antimicrob Agents. 2012 Apr;39(4):311-6. doi: 10.1016/j.ijantimicag.2012.01.002. Epub 2012 Mar 3.

引用本文的文献

1
Optimising Regimen of Co-Amoxiclav (ORCA)-The Safety and Efficacy of Intravenous Co-Amoxiclav at Higher Dosing Frequency in Patients with Diabetic Foot Infection.优化阿莫西林克拉维酸钾治疗方案(ORCA)——糖尿病足感染患者更高给药频率静脉注射阿莫西林克拉维酸钾的安全性和有效性
Antibiotics (Basel). 2025 Jul 28;14(8):758. doi: 10.3390/antibiotics14080758.
2
Empiric Anti-Pseudomonal β-Lactam Monotherapy Versus Fluoroquinolone Combination Therapy in Patients With Hospital-Acquired Pneumonia: A Multicenter Cohort Study With Propensity Score Matching.经验性抗假单胞菌β-内酰胺单药治疗与氟喹诺酮类联合治疗医院获得性肺炎患者:一项倾向评分匹配的多中心队列研究。
J Korean Med Sci. 2023 Oct 23;38(41):e353. doi: 10.3346/jkms.2023.38.e353.
3
Isolation and Characterization of Bacteriophages Active against Strains Isolated from Diabetic Foot Infections.
分离和鉴定针对糖尿病足感染分离株的噬菌体。
Arch Razi Inst. 2022 Dec 31;77(6):2187-2200. doi: 10.22092/ARI.2022.359032.2357. eCollection 2022 Dec.
4
Evidence-Based Treatment of Infections: A Critical Reappraisal.感染的循证治疗:批判性重新评估
Antibiotics (Basel). 2023 Feb 16;12(2):399. doi: 10.3390/antibiotics12020399.
5
Cost-effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia.亚胺培南/西司他丁/雷巴他定治疗医院获得性和呼吸机相关性细菌性肺炎的成本效益。
J Comp Eff Res. 2023 Mar;12(3):e220113. doi: 10.2217/cer-2022-0113. Epub 2023 Jan 23.
6
Prognostic Effects of Inappropriate Empirical Antimicrobial Therapy in Adults With Community-Onset Bacteremia: Age Matters.成人社区获得性菌血症不恰当经验性抗菌治疗的预后影响:年龄很重要。
Front Med (Lausanne). 2022 Apr 11;9:861032. doi: 10.3389/fmed.2022.861032. eCollection 2022.
7
Antimicrobial Susceptibility Trends and Risk Factors for Antimicrobial Resistance in Bacteremia: 12-Year Experience in a Tertiary Hospital in Korea.血流感染中的抗菌药物敏感性趋势和抗菌药物耐药性的危险因素:韩国一家三级医院 12 年的经验。
J Korean Med Sci. 2021 Nov 8;36(43):e273. doi: 10.3346/jkms.2021.36.e273.
8
Advances in Understanding of the Copper Homeostasis in .铜代谢平衡研究进展
Int J Mol Sci. 2021 Feb 19;22(4):2050. doi: 10.3390/ijms22042050.
9
Futuristic Non-antibiotic Therapies to Combat Antibiotic Resistance: A Review.对抗抗生素耐药性的未来非抗生素疗法:综述
Front Microbiol. 2021 Jan 26;12:609459. doi: 10.3389/fmicb.2021.609459. eCollection 2021.
10
Evaluation of efflux pump activity and biofilm formation in multidrug resistant clinical isolates of Pseudomonas aeruginosa isolated from a Federal Medical Center in Nigeria.评价从尼日利亚联邦医疗中心分离的多重耐药铜绿假单胞菌临床分离株的外排泵活性和生物膜形成。
Ann Clin Microbiol Antimicrob. 2021 Feb 2;20(1):11. doi: 10.1186/s12941-021-00417-y.